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Abstract
Background: We aimed to evaluate the prognostic value of quality of life (QOL) for predicting survival among
disease-free survivors of surgically-treated lung cancer after the completion of cancer treatment.
Methods: We administered the European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30), the Quality of Life Questionnaire Lung Cancer Module (QLQ-LC13), Hospital
Anxiety and Depression Scale (HADS), and Posttraumatic Growth Inventory (PTGI) to 809 survivors who were surgically-
treated for lung cancer at two hospitals from 2001 through 2006. We gathered mortality data by linkage to the National
Statistical Office through December 2011. We used Cox proportional hazard models to compute adjusted hazard ratios
(aHRs) and 95 % confidence intervals (CIs) to estimate the relationship between QOL and survival.
Results: Analyses of QOL items adjusted for age, sex, stage, body mass index, and physical activity showed that scores for
poor physical functioning, dyspnea, anorexia, diarrhea, cough, personal strength, anxiety, and depression were associated
with poor survival. With adjustment for the independent indicators of survival, final multiple proportional hazard
regression analyses of QOL show that physical functioning (aHR, 2.39; 95 % CI, 1.13–5.07), dyspnea (aHR, 1.56;
95 % CI, 1.01–2.40), personal strength (aHR, 2.36; 95 % CI, 1.31–4.27), and anxiety (aHR, 2.13; 95 % CI, 1.38–3.30)
retained their independent prognostic power of survival.
Conclusion: This study suggests that patient-reported QOL outcomes in disease-free survivors of surgically-treated
lung cancer after the completion of active treatment has independent prognostic value for long-term survival.
Background
Health Related Quality of life (HRQOL) is an important
clinical outcome for treatment comparisons in cancer
patients [1, 2]. Although advances in early detection and
treatment strategies have increased the likelihood of
survival, lung cancer survivors are known to suffer sub-
stantial symptom burdens [3]. Although earlier studies
suggested that physical symptoms such as anorexia [4],
pain [4–7], and fatigue [4] are the strongest independent
prognostic factors for survival even after the adjustment
for established prognostic variables, mental health
criteria, such as psychological distress, existential well-
being, and posttraumatic growth, would also be inde-
pendent predictive contributors for long-term survival
among long-term cancer survivors [1, 8, 9].
QOL is a critical independent prognostic factor for
predicting survival [10–12]. However, studies regarding
the prognostic value of QOL have primarily focused on
QOL at the time of the diagnosis or treatment at base-
line [13–19]. Prior analyses have also shown that QOL is
an important prognostic factor in patients with advanced
lung cancer [12, 20–24]. measured QOL at the time of
the diagnosis or clinical treatment trials, and no pub-
lished studies have focused on the predictive value of
QOL for long-term survival in disease-free lung cancer
survivors after the completion of cancer treatment. The
identification of prognostic factors might help clinicians
to correctly survey individuals at highest risk for
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recurrence and mortality, and allow for appropriate in-
terventions to improve QOL and survival in disease-free
lung cancer survivors after the completion of active can-
cer treatment [11].
Seven years ago, we conducted a large cross-sectional
study of QOL among cancer survivors who had under-
gone primary curative surgery for stage 0-III lung cancer
between 2001 and 2006, and were disease-free after pri-
mary treatment for lung cancer ended and survived for
longer than 1 year without any evidence of cancer [25].
The QOL measurements that we collected allowed us to
assess the prognostic value of comprehensive QOL vari-
ables, including physical, mental, social, and existential
domains, for predicting long-term survival more than
5 years after the survey completion. In this study, we
aimed to evaluate the prognostic value of QOL, which
provides information on the likely course of cancer mor-
tality by predicting survival among patients with lung
cancer after cancer treatment completion.
Methods
Participants
In 2007, we conducted a survey of lung cancer survivors.
Among 1,633 patients who were contacted at two hospi-
tals in South Korea from 2001 through 2006, we identified
830 survivors who had been surgically-treated for lung
cancer. Among them, we excluded 27 subjects whose sur-
vival status was censored until December 31, 2011. Thus,
a total of 809 patients had been included in this study. All
participants provided written informed consent. We col-
lected information regarding the date of the diagnosis,
stage, type of treatment, and other clinical characteristics
from the hospital cancer registries. This study was ap-
proved by the Institutional Review Boards (IRB) of
National Cancer Center and Samsung Medical Center.
We collected QOL data among cancer survivors who
were disease-free after primary treatment for lung cancer
ended and survived without any evidences of cancer
for longer than one year. Participants filled out a
questionnaire including important survivorship issues
such as QOL, anxiety, depression, and posttraumatic
growth, etc. This study was approved by the Institu-
tional Review Boards of each hospital. Criteria for en-
rollment in this study have been previously described
in detail [25].
Measures
Socio-demographic and clinical variables Through
our systematically organized questionnaire, socio-
demographic variables (age, sex, level of education,
monthly income, employment status, marriage status,
physical activity, smoking, and alcohol consumption)
were assessed. We considered physical activity (PA) to
be at least 30 min of moderate-to-vigorous physical
activity for 5 or more days per week (ie, ≥12.5 meta-
bolic equivalent tasks [26]/week). In addition, clinico-
pathological data (years from the survey date to the
diagnosis date, type of treatment, overweight (a BMI >23
at the time of survey), PA, comorbidities, cancer stage,
time since the diagnosis, and the years from survey date
to the diagnosis date) were collected from the patients’
medical charts and hospital-based cancer registries.
To determine the influence of comorbidities on cancer
patients, we asked patients about the current existence
of comorbidities, such as cerebrovascular disease (eg,
stroke or cerebral hemorrhage), heart disease (eg, angina
pectoris, myocardial infarction, or chronic heart failure),
diabetes, liver disease (eg, chronic hepatitis or cirrhosis),
pulmonary disease (eg, chronic bronchitis or asthma),
hypertension, infectious diseases (eg, tuberculosis, etc.),
digestive diseases (eg, chronic gastritis, gastric ulcer, or
duodenal ulcer), musculoskeletal disorders (eg, degen-
erative or rheumatoid arthritis), kidney disease (eg,
chronic renal failure, etc.).
Health-related quality of life (HRQOL)
Patients completed questionnaires that covered the fol-
lowing characteristics: the European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire Core-30 item (EORTC QLQ-C30) and lung
cancer module (QLQ-LC13), Hospital Anxiety and De-
pression Scale (HADS), and Posttraumatic Growth In-
ventory (PTGI).
The EORTC QLQ-C30 is a 30-item cancer-specific
questionnaire for measuring global health and overall
QOL scales, five functioning domains (physical, role,
cognitive, emotional, and social), three symptom scales
(fatigue, pain, and nausea and vomiting), and six single
items that assess additional symptoms commonly re-
ported by cancer patients (dyspnea, appetite loss, sleep
disturbance, constipation, and diarrhea) along with any
perceived financial difficulties [18]. The QLQ-LC13
incorporates one multi-item scale (dyspnea) and nine
single items (pain in the arm/shoulder, chest, and other
organs; cough; hemoptysis; dysphagia; peripheral neur-
opathy; alopecia; mouth sores). In both surveys, high
scores represent better functioning and severe symptoms.
HADS is a self-reported assessment tool comprised of two
domains: the anxiety subscale and the depression subscale
[27]. Each of the two HADS-subscales was measured
using seven items rated on a 4-point Likert scale ranging
from no feelings of anxiety or depression (0) to severe
feelings of anxiety or depression [3]. Total scores ranged
from 0 to 21 for each anxiety and depression subscale.
The PTGI includes 21 items regarding positive changes,
with five domains relating to others, personal strength,
new possibilities, appreciation of life, and spiritual change.
Each question was scored from 0 to 5 using a 6-point
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Likert scale. A higher score signifies greater posttraumatic
positive growth [28].
Survival data
The patients were followed regularly by each hospital
registries after the completion of treatment. If the patients
died during that follow-up, the family caregivers were
asked the date of death. We also gathered mortality data
by linkage to the National Statistical Office. We measured
survival time from the date of the diagnosis and used mor-
tality data with vital status. The person-years at risk data
were accumulated for each patient from the date of the
survey to the date of death. During the follow-up of
4509.2 person-years, we identified 96 deaths (11.9 %)
among the 809 subjects. In the 809 lung cancer survivors
for whom there were available data, the median time from
the diagnosis to survey date was 6.0 (±1.24) years and the
median survival time was 8.3 (±2.01) years.
Statistical analyses
First, we performed univariate analyses of the aforemen-
tioned demographic and clinical characteristics with the
mortality of the lung cancer survivors. Variables that
were significant in the univariate analyses were included
in the adjusted multiple proportional hazard regression
analyses to identify independent prognostic indicators of
survival, which formed the baseline prognostic model
using a backward feature selection method.
Next, we performed analyses to determine whether
HRQOL scores (EORTC QLQ, HADS, and PTGI) were
significantly associated with survival using Cox propor-
tional hazard models. Due to the high statistical collinear-
ity problem among the HRQOL variables, each factor was
first analyzed separately in the Cox proportional hazard
model, which incorporated the baseline prognostic model
(specifically age, sex, stage, BMI, and PA) to identify inde-
pendent HRQOL predictors of long-term survival.
To maximize differences in prognostic strength of
QOL scores, we dichotomized each variable score and
chose a cut-off point. We dichotomized each scale of
EORTC QLQ-C30 and EORTC QLQ-LC13 based on the
score for the problematic group: ≤33 on a scale of 0–100
for global QOL or functioning scale, and >66 for symp-
tom scale [29]. Earlier studies with cancer survivors have
shown that the scores for the problematic group were
useful in identifying the problems of QOL compared
with general population [30, 31] In addition, we used
HADS as the outcome measure, which was dichoto-
mized with the cut-off point of 8 as a borderline case of
anxiety or depression [32]. For PTGI, we dichotomized
each variable according to the standardized manual [28].
Finally, we constructed the final model for long-term
survival using demographic and clinical characteristics
and QOL scores that were identified as independent
prognostic indicators of survival with adjusted multiple
proportional hazard regression analyses; then, we traced
survival curves of the significant QOL factors using
PROC LIFETEST. We calculated adjusted hazard ratios
(aHRs) and 95 % confidence intervals (CIs). A p-value of
less than 0.05 was considered to indicate statistical sig-
nificance and used to identify significant factors retain-
ing in the model. The SAS statistical package version 9.3
(SAS Institute Inc., Cary, NC) was used for all analyses.
Results
Univariate analyses and multiple proportional hazard
regression analyses of demographic and clinical
characteristics
Table 1 summarizes the baseline demographic and clinical
characteristics, as well as crude and adjusted hazard ratios
(HRs) for the overall survival from Cox proportional
hazards regression models. Table 2 summarized multiple
proportional hazard regression analyses using a backward
feature selection method with variables that were signifi-
cant in univariate analyses showed that age, sex, stage of
cancer, monthly Income, BMI of overweight indicator, and
PA had independent prognostic value.
Univariate analyses and adjusted proportional hazard
regression analyses of QOL, PTGI, and HADS
Table 2 summarizes the multiple proportional hazard re-
gression analyses using a backward feature selection
method with variables that were significant in the uni-
variate analyses showing that age, sex, stage of cancer,
monthly income, BMI of overweight indicator, and PA
showed that the scores of physical functioning (aHR
3.44, 95 % CI 1.72–6.88), dyspnea (aHR 1.96, 95 % CI
1.30–2.95), anorexia (aHR 1.68, 95 % CI 1.00–2.82), diar-
rhea (aHR 2.11, 95 % CI 1.01–4.40), and cough (aHR
1.92, 95 % CI 1.15–3.20) for the problematic group were
associated with poor survival. Additionally, Table 3 sum-
marizes the crude and adjusted HRs for the association
between PTGI and HADS with the risk of overall
survival. Survivors with poor personal strength (aHR
2.43, 95 % CI 1.35–4.38), anxiety (aHR 2.55, 95 % CI
1.68–3.87), or depression (aHR 1.73, 95 % CI 1.16–2.60)
showed significantly diminished length of survival.
Final multiple proportional hazard regression analyses of
QOL adjusted for independent demographic and clinical
indicators of survival
After adjustment for independent demographic and clin-
ical indicators of survival, the final multiple proportional
hazard regression analyses of QOL showed that physical
functioning (aHR 2.39, 95 % CI 1.13–5.07) and dyspnea
(aHR 1.56, 95 % CI 1.01–2.40) from the EORTC QLQ-
C30, personal strength (aHR 2.36, 95 % CI 1.31–4.27)
from the PTGI, and anxiety (aHR 2.13, 95 % CI 1.38–
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3.30) from the HADS did not lose their independent
prognostic power of survival (Table 4 and Fig. 1). In
addition, an overweight BMI >23 decreased the hazard
of mortality in the final model (aHR for a BMI <23; 1.75,
95 % CI 1.16–2.64; Table 4).
Discussion
The data obtained from this study suggest that QOL defi-
cits after completion of lung cancer treatment are signifi-
cantly associated with the prognosis for overall survival
(OS). Because clinicians and patients need more informa-
tion on the patient’s prognosis in terms of the disease-free
interval after the completion of cancer treatment when la-
boratory and imaging techniques cannot provide more
prognostic information than the known prognostic
factors, a QOL assessment in disease-free lung cancer sur-
vivors at the completion of cancer treatment would con-
tribute significantly to predicting patient survival.
After controlling for these covariates, the indication of
a clinically-deficient QOL after attaining disease-free sta-
tus remains clinically meaningful. Therefore, these find-
ings highlight the importance of assessing QOL in
survivors after completion of lung cancer treatment.
To the best of our knowledge, this is the first study to
report on the prognostic value of QOL scores using a
large sample of disease-free survivors with lung cancer
after the completion of lung cancer treatment. Our find-
ings are consistent with those of other studies that inves-
tigated the importance of pretreatment QOL assessment
in patients with non-small cell lung cancer (NSCLC)
Table 1 Clinical and Socio-demographic characteristics and mortality of lung cancer survivors (n = 809)
Variable No. of deaths/No. of participants Crude HR 95 % CI aHRa 95 % CI
Age (years) <65 33/426 1.00 1.00
≥65 63/383 2.28 1.49 3.47 1.99 1.30 3.05
Sex Female 10/187 1.00 1.00
Male 86/622 2.71 1.41 5.22 2.34 1.21 4.53
Education ≥High school degree 20/205 1.00
<High school degree 76/604 1.31 0.80 2.15 NS
Monthly Income(USD) ≥3,000 13/220 1.00
<3,000 83/589 2.49 1.39 4.47 NS
Employment status yes 30/315 1.00
no 66/494 1.46 0.95 2.25 NS
Currently married yes 89/744 1.00
no 7/65 0.90 0.42 1.94 NS
Stage stage 0–I 46/510 1.00 1.00
stage II–III 50/299 1.92 1.29 2.86 1.80 1.20 2.70
Comorbidity no 45/363 1.00
yes 51/443 0.93 0.62 1.39 NS
BMI at the time of survey (kg/m2) ≥23 39/452 1.00 1.00
<23 56/355 1.92 1.28 2.89 1.70 1.12 2.57
Alcohol Now NO 75/623 1.00
Yes 21/186 0.92 0.57 1.50 NS
Current smoking status no 89/750 1.00
yes 7/59 0.99 0.46 2.14 NS
MET ≥12.5 43/443 1.00 1.00
<12.5 53/363 1.55 1.03 2.31 1.54 1.02 2.31
Type of treatment Surgery 54/485 1.00
Surgery and otherb 42/318 1.47 0.77 2.81 NS
Years from survey date to diagnosis date ≤3 years 37/343 1.00
>3 years 59/466 1.20 0.79 1.80 NS
Abbreviations: HR hazard ratio, aHR adjusted hazard ratio, BMI body mass index, MET metabolic equivalent task
aMultiple proportional hazard regression analysis adjusted with age, sex, education, income, employment status, stage, comorbidity, BMI, alcohol drinking, current
smoking, MET, treatment type, years from survey date to diagnosis date
bother was Radiotherapy and Chemotherapy
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Table 2 Univariate analyses and adjusted proportional hazard regression analyses of QOL
Variable No. of deaths/No. of participants Crude HR 95 % CI aHRa 95 % CI
EORTC-QCQ -C30 Physical functioning >33.33 87/783 1 1
≤33.33 9/26 3.71 1.87 7.36 3.44 1.72 6.88
Role functioning >33.33 89/782 1 1
≤33.33 7/27 2.51 1.16 5.41 2.14 0.99 4.65
Emotional functioning >33.33 92/792 1 1
≤33.33 4/17 2.12 0.78 5.77 2.59 0.94 7.14
Cognitive functioning >33.33 94/793 1 1
≤33.33 2/16 1.08 0.27 4.37 0.95 0.23 3.90
Social functioning >33.33 91/786 1 1
≤33.33 5/23 1.99 0.81 4.88 1.56 0.63 3.88
General health status >33.33 89/770 1 1
≤33.33 7/39 1.62 0.75 3.49 1.35 0.62 2.93
Fatigue <66.66 83/720 1 1
≥66.66 13/89 1.30 0.72 2.33 1.24 0.69 2.24
Nausea & vomiting <66.66 94/790 1 1
≥66.66 2/19 0.91 0.23 3.73 0.82 0.20 3.33
Pain <66.66 87/752 1 1
≥66.66 9/57 1.41 0.71 2.80 1.28 0.61 2.66
Dyspnea <66.66 53/591 1 1
≥66.66 43/218 2.33 1.56 3.48 1.96 1.30 2.95
Insomnia <66.66 79/689 1 1
≥66.66 17/120 1.24 0.73 2.09 1.27 0.75 2.16
Appetite loss <66.66 76/717 1 1
≥66.66 20/92 2.20 1.35 3.61 1.68 1.00 2.82
Constipation <66.66 87/746 1 1
≥66.66 9/63 1.24 0.63 2.47 1.13 0.57 2.27
Diarrhea <66.66 88/773 1 1
≥66.66 8/36 2.13 1.03 4.39 2.11 1.01 4.40
Financial difficulties <66.66 77/686 1 1
≥66.66 19/123 1.39 0.84 2.30 1.14 0.68 1.89
EORTC-QCQ -LC13 Dyspnea <66.66 77/733 1 1
≥66.66 19/76 2.62 1.59 4.33 2.26 1.36 3.76
Coughing <66.66 77/726 1 1
≥66.66 19/83 2.35 1.42 3.88 1.92 1.15 3.20
Hemoptysis <66.66 95/803 1 1
≥66.66 1/6 1.35 0.19 9.67 0.82 0.11 5.94
Sore mouth <66.66 90/782 1 1
≥66.66 6/26 2.15 0.94 4.91 1.83 0.80 4.19
Dysphagia <66.66 90/783 1 1
≥66.66 6/26 2.18 0.96 4.99 1.62 0.70 3.74
Peripheral neuropathy <66.66 84/725 1 1
≥66.66 12/84 1.28 0.70 2.35 1.29 0.70 2.37
Alopecia <66.66 89/756 1 1
≥66.66 7/52 1.17 0.54 2.53 1.26 0.58 2.74
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[12, 33, 34]. Earlier studies suggested that pretreatment
scores for global QOL [5, 6], anorexia [4], pain [4–7],
and fatigue [4] are the strongest independent prognostic
factors, even after the adjustment for established prog-
nostic variables such as age, sex, and stage.
The prognosis of disease-free survivors with NSCLC is
significant for both clinical and basic research [20]. The
identification of prognostic factors can help provide in-
formation for cancer survivors, as well as aid physicians
in choosing the best methods for surveillance and inter-
vention. In addition, prognostic QOL factors including
survivors’ overall functioning and well-being can be used
as supportive monitoring tools in oncology practice [2, 35].
However, no previous studies have addressed the prognos-
tic significance of QOL scores for disease-free lung cancer
survivors who are regarded to have a relatively good prog-
nosis after the completion of active cancer treatment.
Symptoms such as anorexia, fatigue, cough, dyspnea, and
pain were associated with pro-inflammatory cytokines and
vascular endothelial growth factor levels that were signifi-
cantly related to survival [4]. Although analyses of QOL
items adjusted for age, sex, stage, BMI, and PA showed that
the scores for the problematic group displaying anorexia,
diarrhea, fatigue, cough, and depression were associated
with poor survival, they did lose their independent prog-
nostic power of survival in the final multiple proportional
hazard regression analyses. Anorexia, diarrhea, and fatigue
could be a cause or a consequence of malnutrition, or indi-
cative of subsequent deterioration in the general health
status of patients with cancer [36].
Table 2 Univariate analyses and adjusted proportional hazard regression analyses of QOL (Continued)
Pain in chest <66.66 80/727 1 1
≥66.66 16/82 1.85 1.08 3.16 1.70 0.98 2.95
Pain in arm or shoulder <66.66 82/699 1 1
≥66.66 14/110 1.09 0.62 1.93 1.22 0.69 2.15
Pain in other body parts <66.66 83/726 1 1
≥66.66 12/82 1.32 0.72 2.43 1.44 0.78 2.65
Abbreviations: HR hazard ratio, aHR adjusted hazard ratio, CI confidence interval
aEach of the multiple proportional hazard regression analysis was adjusted for age, sex, stage, BMI at the time of survey, and MET
Table 3 Univariate analyses and adjusted proportional hazard regression analyses of PTGI and HADS
Variable No. of deaths/No. of participants Crude HR 95 % CI aHRa 95 % CI
PTGI
Relation to others ≥23 35/332 1 1
<23 61/477 1.24 0.82 1.88 1.26 0.83 1.92
New possibilities ≥18 13/177 1 1
<18 77/578 1.88 1.04 3.38 1.73 0.94 3.18
Personal strength ≥15 14/237 1 1
<15 82/572 2.56 1.45 4.5 2.43 1.35 4.38
Spiritual change ≥5 40/407 1 1
<5 56/402 1.45 0.97 2.18 1.34 0.89 2.02
Appreciation of life ≥11 33/361 1 1
<11 63/448 1.59 1.04 2.42 1.47 0.96 2.25
Total ≥71 23/279 1 1
<71 73/526 1.75 1.1 2.8 1.67 1.03 2.69
HADS
Anxiety <8 59/634 1 1
≥8 36/170 2.41 1.6 3.65 2.55 1.68 3.87
Depression <8 45/490 1 1
≥8 51/313 1.83 1.23 2.74 1.73 1.16 2.6
Abbreviations: HR hazard ratio, aHR adjusted hazard ratio, CI confidence interval, PTGI posttraumatic growth inventory, HADS hospital anxiety and depression scale
aMultiple proportional hazard regression analysis adjusted with age, sex, education, income, employment status, stage, comorbidity, BMI, alcohol drinking, current
smoking, MET, treatment type, years from survey date to diagnosis date
Yun et al. BMC Cancer  (2016) 16:505 Page 6 of 10
Physical functioning, dyspnea, personal strength, and
anxiety did not lose their independent prognostic power
of survival in the final multiple proportional hazard
regression analyses of QOL with independent demo-
graphic and clinical indicators of survival. These results
could be due to prognostic factors other than QOL
scores, and different cut-offs used to dichotomize each
scale. Additionally, it is possible that anorexia, diarrhea,
fatigue, cough, and depression are strong prognostic
variables for survival in advanced lung cancer during
clinical trials or after the treatment [24, 33]. Physical
functioning, dyspnea, personal strength, and anxiety are
likely to have a better prognostic value than anorexia,
diarrhea, fatigue, cough, and depression in disease-free
lung cancer survivors.
These findings may indicate a disease progression or
recurrence that physical examination by a clinician,
tumor marker evaluation, and imaging studies (such as
computed tomography, magnetic resonance imaging,
and positron emission tomography) could not detect
[23]. It is also possible that individuals with poor QOL,
or those who are not motivated, may be less likely to
adhere to their medical treatment plans [12] and good
health behaviors (such as moderate-to-vigorous PA) that
are independent predictors of mortality in disease-free
lung cancer survivors [23, 37, 38]. Therefore, this study
suggests the possibility of new prognostic value reflect-
ing long-term survival in disease-free survivors with lung
cancer after the completion of active treatment [23].
These findings must be validated prospectively in further
studies that should investigate QOL, adherence to can-
cer treatment, psychoneuroimmunology [13], circulating
tumor cells [39], and survival in a different cohort of pa-
tients with lung cancer [36].
Additionally, intervention studies will be required to
examine the possibility that interventions designed for
improving QOL, such as physical functioning, anxiety,
and personal strength in patients with lung cancer, may
improve survival [12, 40].
Our findings indicate that assessment of QOL should
be incorporated into routine oncology clinical practice
[21, 24]. This may present certain obstacles, such as an
increased burden on the patient [7]. However, if the ad-
vantage of such a comprehensive assessment outweighs
the disadvantage of its poor applicability in clinical
practice [5], repeated assessment of QOL would have
significant importance in medical decisions such as the
diagnosis of progression and clinical intervention. Our
next objective is to develop and test a predictive model
for survival in order to identify patients who are experi-
encing deficits in QOL. The use of a simple questionnaire
in clinical practice may benefit patients and provide
specific interventions tailored to improve patient QOL
and survival [12].
This study has limitations in interpretation and
generalization. First, it included only disease-free lung
cancer patients from selected hospitals who survived at
least 1 year after surgery. Thus, it might not represent
the general population of lung cancer survivors. Second,
we lacked evaluations of QOL changes over time. QOL
values are dynamic, and changes might be associated
with long-term survival. Third, this study only addressed
overall mortality and did not include cancer-specific
mortality and non-cancer mortality. Further studies that
include cancer-specific mortality and non-cancer mor-
tality would be helpful for interpreting the prognostic
value of QOL in lung cancer. Finally, the participants
were surveyed at different time intervals from the time
of their diagnosis; we have adjusted for this as a co-
variable.
Conclusion
This prospective study of a large cohort of survivors
with lung cancer suggests that patient-reported QOL
outcomes after the completion of active treatment has
independent prognostic value for long-term survival. We
propose that the assessment of QOL should be incorpo-
rated into routine oncology clinical practice.
Table 4 Multiple proportional hazard regression analyses of QOL
adjusted for independent demographic and clinical indicators of
survival
Variable aHRa 95 % CI
Age (years) <65 1
≥65 1.84 1.19 2.83
Sex Women 1
Men 2.52 1.29 4.93
Stage stage 0–I 1
stage II–III 1.70 1.13 2.56
BMI at the time of survey (kg/m2) ≥23 1
<23 1.75 1.16 2.64
Physical functioning >33.33 1
≤33.33 2.39 1.13 5.07
Dyspnea <66.66 1
≥66.66 1.56 1.01 2.40
PTGI_Personal strength ≥15 1
<15 2.36 1.31 4.27
HADS_Anxiety <8 1
≥8 2.13 1.38 3.30
Abbreviations: aHR adjusted hazard ratio, CI confidence interval, BMI body mass
index, PTGI posttraumatic growth inventory, HADS hospital anxiety
and depression
aFinal model of multiple proportional hazard regression analysis including
variables identified as independent predictors that showed statistical
significance in each of univariate analyses and adjusted proportional hazard
regression analyses including QOL
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Fig. 1 Survival graph by among Lung Cancer Patients. Abbreviations: CI, Confidence Interval; Reference was the non-problematic group. a The hazard ratio
was multivariable-adjusted for age at diagnosis, sex, cancer stage, BMI after surgery, dyspnea, personal strength, and anxiety. The problematic group for
physical functioning was defined as one with a health related quality of life (HRQOL) score of 33or less. b The hazard ratio was multivariable-adjusted for
age at diagnosis, sex, cancer stage, BMI after surgery, physical functioning, personal strength, and anxiety. The problematic group for dyspnea was defined
as one with a symptom scale score of 66 or higher. c The hazard ratio was multivariable-adjusted for age at diagnosis, sex, cancer stage, BMI after surgery,
physical functioning, dyspnea, and anxiety. The problematic group for personal strength was defined as one with a PTGI factor of 15 or less. d The hazard
ratio was multivariable-adjusted for age at diagnosis, sex, cancer stage, BMI after surgery, physical functioning, dyspnea, and personal strength. The
problematic group for Anxiety was defined as one with a HADS of 8 or higher
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Abbreviation
BMI, body mass index; HADS, hospital anxiety and depression scale; HRQOL,
health related quality of life; NSCLC, non-small cell lung cancer; OS, overall
survival; PA, physical activity; PTGI, posttraumatic growth inventory
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